Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326673 | 0.81 | POLB (0.33) | POLBBRD4 | |
| SCHEMBL14437893 | 0.80 | POLB (0.32) | MAPTPOLB | |
| SCHEMBL12088177 | 0.80 | POLB (0.31) | POLB | |
| SCHEMBL18179999 | 0.80 | CHRM1 (0.32) | BRD4 | |
| SCHEMBL10068094 | 0.80 | CHRM2 (0.33) | HPGDBRD4 | |
| SCHEMBL16856451 | 0.79 | POLB (0.32) | POLB | |
| SCHEMBL12642095 | 0.79 | ADAM17 (0.44) | POLB | |
| SCHEMBL6802326 | 0.79 | POLB (0.32) | POLB | |
| SCHEMBL23071802 | 0.79 | BRD4 (0.31) | BRD4 | |
| SCHEMBL208987 | 0.79 | PRKCA (0.35) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3737418-B1 | POLYMERS WITH RIGID SPACING GROUPS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | SONY GROUP CORP (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20230285580-A1 | ANTI-IL-13RALPHA2 CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2023-09-14 | — | — | US | disclosed |
| US-20220153697-A1 | RIGIDIFIED PENTADENTATE CHELATING AGENTS USEFUL FOR THE [AL18F]2+ LABELLING OF BIOMOLECULES | UNIVERSITÀ DEGLI STUDI DEL PIEMONTE ORIENTALE "A. AVOGADRO" (IT) | 2022-05-19 | — | — | US | disclosed |
| EP-3512856-B1 | NOVEL CYTOTOXIC AGENTS AND CONJUGATES THEREOF | POLYTHERICS LTD (GB) | 2021-03-24 | — | — | EP | disclosed |
| EP-3753578-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | Novartis AG (CH) | 2020-12-23 | — | — | EP | disclosed |
| US-10633418-B2 | Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method | JITSUBO CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| US-20170354743-A1 | SITE SELECTIVE CONJUGATION OF AN OLIGONUCLEOTIDE CONJUGATE OR A SMALL MOLECULE TO A METAL BINDING PROTEIN | AFFYCON APS (DK) | 2017-12-14 | — | — | US | disclosed |
| US-20170340752-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2017-11-30 | — | — | US | disclosed |
| US-9821074-B2 | Pyrrolobenzodiazepines and conjugates thereof | GENENTECH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170258934-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2017-09-14 | — | — | US | disclosed |
| US-7588701-B2 | Cored dendrimer comprising crosslinked dendrons surrounding a central interior region that is free of organic material, a semiconductor particle within cored dendrimer, having a size that is no greater than an outer dimension of cored dendrimer and that is greater than central interior region | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080265221-A1 | TEMPLATED SEMICONDUCTOR PARTICLES AND METHODS OF MAKING | 3M INNOVATIVE PROPERTIES COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-7413607-B2 | Templated semiconductor particles and methods of making | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080152911-A1 | TEMPLATED METAL PARTICLES AND METHODS OF MAKING | 3M INNOVATIVE PROPERTIES COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-7344583-B2 | Methods of making metal particles within cored dendrimers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7316931-B2 | Mass defect labeling for the determination of oligomer sequences | TARGET DISCOVERY, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | ISHII YASUTAKA | 2006-12-14 | — | — | US | disclosed |
| US-7115541-B2 | Catalyst comprising n-substituted cyclic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1338336-A1 | CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20030013603-A1 | Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153697-A1 | RIGIDIFIED PENTADENTATE CHELATING AGENTS USEFUL FOR THE [AL18F]2+ LABELLING OF BIOMOLECULES | SLC29A1, APRT, SLC29A2 | MAPT 2824/4885HPGD 4486/4885POLB 2500/4885 |
| US-20170258934-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | IL2RA, CD2, CD4 | MAPT 913/4885HPGD 361/4885POLB 3203/4885 |
| US-20230285580-A1 | ANTI-IL-13RALPHA2 CONJUGATES | IL2RA, IL15RA, IL23R | MAPT 2402/4885HPGD 2742/4885POLB 3661/4885 |
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | NOS2, NOS1, NOS3 | MAPT 4792/4885HPGD 301/4885POLB 2011/4885 |
| US-10633418-B2 | Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method | VIP, NRDC, PTMS | MAPT 3566/4885HPGD 1567/4885POLB 2337/4885 |
| US-20170354743-A1 | SITE SELECTIVE CONJUGATION OF AN OLIGONUCLEOTIDE CONJUGATE OR A SMALL MOLECULE TO A METAL BINDING PROTEIN | CD2BP2, CACYBP, CALCOCO2 | MAPT 3397/4885HPGD 4659/4885POLB 1378/4885 |
| US-20170340752-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD22, GABRA1, CCNB1 | MAPT 4431/4885HPGD 3753/4885POLB 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.